Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 20/20 | 0.79 |
| ▸ | PIK3CD | O00329 | 19/20 | 0.79 |
| ▸ | PIK3CA | P42336 | 17/20 | 0.79 |
| ▸ | PIK3CB | P42338 | 17/20 | 0.79 |
| ▸ | PIK3R2 | O00459 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17657858 | 1.00 | PIK3CG (0.79) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3R2 | |
| SCHEMBL17657995 | 1.00 | PIK3CG (0.79) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3R2 | |
| SCHEMBL17657253 | 0.92 | PIK3CD (0.79) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3R2 | |
| SCHEMBL17658068 | 0.92 | PIK3CD (0.79) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3R2 | |
| SCHEMBL17657906 | 0.92 | PIK3CD (0.79) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3R2 | |
| SCHEMBL17657268 | 0.92 | PIK3CD (0.67) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3R2 | |
| SCHEMBL17658028 | 0.92 | PIK3CD (0.67) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3R2 | |
| SCHEMBL17657862 | 0.92 | PIK3CD (0.67) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3R2 | |
| SCHEMBL17658021 | 0.90 | PIK3CD (0.67) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3R2 | |
| SCHEMBL17657834 | 0.90 | PIK3CD (0.67) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10941162-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20190330240-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2019-10-31 | — | — | US | disclosed |
| US-10253047-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20170369511-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2017-12-28 | — | — | US | disclosed |
| US-9708348-B2 | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708348-B2 | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160122365-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2016-05-05 | — | — | US | disclosed |
| US-20160122365-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2016-05-05 | — | — | US | disclosed |
| WO-2016054491-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2016-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369511-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PIK3CG 7/4885PIK3CD 2/4885PIK3CA 1/4885 |
| US-20160122365-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PIK3CG 7/4885PIK3CD 2/4885PIK3CA 1/4885 |
| US-10941162-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | PIK3CG 4/4885PIK3CD 2/4885PIK3CA 1/4885 |
| US-20190330240-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PIK3CG 7/4885PIK3CD 2/4885PIK3CA 1/4885 |
| US-10253047-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | PIK3CG 6/4885PIK3CD 2/4885PIK3CA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.